LLY
StockEli Lilly and Co
- HQ
- US
- Sector
- Pharmaceuticals
- Issued
- 1985-01-13
- Shares out.
- 942M
Performance
1 h agoKey statistics
1 h ago- Market cap
- $1.02T
- Enterprise value
- $1.05T
- P/E (TTM)
- 40.16
- Forward P/E
- 27.51
- P/E (annual)
- 49.19
- PEG
- 1.37
- P/B
- 38.29
- P/S (TTM)
- 14.05
- P/S (annual)
- 15.58
- EV / EBITDA
- 31.38×
- EV / Revenue
- 14.58×
- EPS (TTM)
- $28.15
- EPS (annual)
- $22.95
- Basic EPS (TTM)
- $28.15
- Book value / share
- $28.09
- Gross margin
- 82.83%
- Operating margin
- 43.63%
- Net margin
- 34.99%
- Return on equity (ROE)
- 101.31%
- Return on assets (ROA)
- 22.73%
- Return on investment (ROI)
- 37.71%
- EBITDA / share
- $37.37
- Revenue / share (TTM)
- $80.64
- Revenue growth (TTM YoY)
- +47.44%
- Revenue growth (Q YoY)
- +55.55%
- EPS growth (TTM YoY)
- +128.83%
- Dividend yield (indicated)
- 0.64%
- Dividend yield (TTM)
- 0.55%
- Dividend / share (TTM)
- $5.91
- Payout ratio
- 22.10%
- Current ratio
- 1.58
- Quick ratio
- 0.78
- Debt / equity
- 1.60
- LT debt / equity
- 1.54
- Beta
- 0.52
- Volatility (3M)
- 37.57%
Analyst ratings
1 h agoEarnings
1 h agoRelated news
1 h ago- Yahoo·7 d agocompanyTop Midday Stories: Micron's Market Cap Briefly Hits $1 Trillion; Qualcomm Reportedly Strikes AI Chip Deal With ByteDance
The Nasdaq Composite and S&P 500 were up, while the Dow Jones Industrial Average was down slightly t
- Yahoo·7 d agocompanyNational Advertising Division Recommends Noom Modify or Discontinue “A Smaller Dose. A Smarter Start” Claim for Microdose GLP-1 Program
In a challenge brought by Eli Lilly and Company, BBB National Programs’ National Advertising Division recommended that Noom, Inc. modify or discontinue its Microdose GLP-1RX Program “A Smaller Dose. A SmarterStart” claim.New York, NY, May 26, 2026 (GLOBE NEWSWIRE) -- In a challenge brought by Eli Lilly and Company, BBB National Programs’ National Advertising Division recommended that Noom, Inc. modify or discontinue its Microdose GLP-1RX Program “A Smaller Dose. A SmarterStart” claim. Lilly and
- Yahoo·7 d agocompanyCan EU Label Expansions of NVO's GLP-1 Drugs Spur Sales Growth?
Novo Nordisk's EU label expansions may widen semaglutide use and boost volumes, but pricing pressure and Lilly rivalry can limit recovery.
- Yahoo·7 d agocompanyMicron tops $1 trillion in market cap as UBS sees company becoming an AI giant
Micron stock rose after UBS said the AI boom has changed the memory chip market — and tripled its price target to a Street high.
- Yahoo·7 d agocompanyMicron briefly tops $1 trillion in market cap as UBS sees company becoming an AI giant
Micron stock rose after UBS said the AI boom has changed the memory chip market — and tripled its price target to a Street high.
- Benzinga·7 d agocompanyFrom Shingles To Superbugs: Eli Lilly Expands Infectious Disease Push In Billion-Dollar Buying Wave
Eli Lilly acquires Curevo, LimmaTech, and Vaccine Co. to expand its infectious disease portfolio and advance long-term disease prevention.
- Benzinga·7 d agocompanyB of A Securities Maintains Buy on Eli Lilly, Raises Price Target to $1251
B of A Securities analyst Jason Gerberry maintains Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $1133 to $1251.
- Yahoo·7 d agocompanyEli Lilly to buy trio of vaccine developers in $3.8bn outlay
Via the deals, Lilly is buying biotechs with lead programmes in preventing shingles, bacteria, and Epstein-Barr Virus.
